Sign in
CompletedPhase 2

Impact of Post-Traumatic Stress Disorder Treatment by Reconsolidation Therapy on Fibromyalgia Syndrome

Key facts

Who runs it
Centre Hospitalier Henri Laborit
Where
France2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
17 people enrolled
Started
13 Aug 2021
Ended
13 Jan 2025
Type of study
Interventional
Treatments tested
  • Propranolol
Record updated
9 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Adult over 18 years old
  • Diagnosis of fibromyalgia syndrome according to ACR 2016 criteria
  • PCL-5 > 44 suggesting the presence of a comorbid post-traumatic stress disorder
  • Meet the DSM-5 criteria for post-traumatic stress disorder secondary to exposure to a traumatic event according to DSM-5 criteria, both unique or repeated and regardless of the date or location of the traumatic event
  • Pain relief treatment and/or psychotropic treatment stabilized for a period greater than or equal to two months
  • Signature of a consent form
  • Patient able to understand and read french

Who cannot take part

  • Adverse reactions or previous intolerances to a beta blocker
  • Current intake of a drug with potential contraindication with the propranolol, according to the summary of product characteristics of the propranolol
  • Psychotic disorders
  • Unstable bipolar disorder
  • Patients with a systolic blood pressure < 100 mmHg or heart rate < 55 as established during the initial visit
  • Significant anormal ECG
  • Medical contraindication to taking propranolol
  • Current intake of another beta blocker which can not be stopped during the protocol, regardeless the galenic
  • Patient under legal protection, under guardianship or under curatorship
  • Patient having suffered a head trauma for less than a year or with clinical symptoms and neurological sequelae
  • Known severe suicide risk (MINI-S and medical exam)
  • Current opioid addiction or alcohol dependence
  • Patients treated for less than 2 months with antidepressants or painkillers
  • Patients unafiliated to a social health care
  • Woman who is pregnant or breast-feeding or whithout efficient contraception

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of the study is to demonstrate a significant improvement in quality of life specific to patients with fibromyalgia syndrome in patients with fibromyalgia syndrome with comorbid posttraumatic stress disorder, treated with reconsolidation blockade.

Read full original descriptionShow less

Patients receive a treatment with propranolol associated with reconsolidation blockade of traumatic story once a week during 6 weeks, with evaluation at inclusion and at 3 months.

The group in the trial

  • Treatment with reconsolidation therapyTreatment being tested

    Patient will take propranolol once a week during 6 weeks. The dosage of propranolol: 1 mg/kg propranolol form: tablet

    Treatment: Propranolol

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
9 September 2026